Portfolio

  • FineHeart makes Fierce Medtech’s 2018 List

    February 11, 2019

    February 11, 2019. FineHeart makes Fierce Medtech’s 2018 list of 15 exciting/innovative companies to watch. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today. Read more here

    Read More
  • Broadview Ventures 2018 Annual Report

    February 6, 2019

    Broadview Ventures 2018 Annual Report

    Read More
  • Vectorious Medical Technologies Announces World’s First In-Heart Microcomputer for Left Atrial Pressure Monitoring

    February 4, 2019

    Tel-Aviv, Israel (4 February, 2019) – Vectorious Medical Technologies, a medical device company enabling optimal management for heart failure patients, today announced the initiation of the VECTOR-HF First-in-Human (FIH) clinical trial, and the successful first ‘in-human’ implantation of the V-LAPTM monitoring device. Link to Press Release  

    Read More
  • Remedy Publication: Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial

    December 4, 2018

    Link to publication

    Read More
  • ZZ Biotech Publication: Final Results of the RHAPSODY Trial

    November 9, 2018

    Link to publication

    Read More
  • Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

    November 5, 2018

    COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound in cardioversion, AP30663. The results of the study demonstrated that intravenous AP30663 was well tolerated with ascending doses, with no significant adverse events.  Link to Press Release

    Read More
  • AtaCor Medical Raises $8.8M to Develop Substernal Cardiac Pacing System

    September 18, 2018

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-based aMoon Ventures, the financing also includes participation from a corporate partner. The investment will support the continued development of AtaCor’s revolutionary extravascular substernal cardiac pacing system. Link to Press Release

    Read More
  • Aeromics Initiates Phase 1 Clinical Trial of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

    July 10, 2018

    BRANFORD, Conn., July 9, 2018 /PRNewswire/ -- Aeromics, Inc. ("Aeromics" or "the Company"), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic stroke, announced today the initiation of a Phase 1 clinical trial in healthy volunteers of its first-in-class drug candidate, AER-271. Link to Press Release

    Read More
  • CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC Device

    May 17, 2018

    TORONTO, Canada, May 17, 2018 – CellAegis Devices Inc. (“CellAegis” or the “Company”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial (“CONDI 2”) to further assess the efficacy of remote ischemic conditioning (“RIC”) in reducing clinical events in patients presenting with ST-segment-elevation myocardial infarction (“STEMI”) and receiving point of care treatment by pa

    Read More
  • CellAegis to complete enrollment in U.S. autoRIC trial by end of 2018

    May 8, 2018

    In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its own U.S. pivotal trial for the treatment of elective percutaneous coronary intervention (ePCI) to complete enrolment before the end of 2018. Link to Press Release

    Read More